# Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus

Study · id `cardio:ct-nct04670666` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04670666](<https://clinicaltrials.gov/study/NCT04670666>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04670666

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 270 participants.

## Technical summary

Registry record NCT04670666. Randomized; double masking; primary purpose treatment. Start 2024-11-18 (actual); primary completion 2026-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 270 participants (planned count; ClinicalTrials.gov record NCT04670666, source copy `cardio:ctgov-nct04670666-2025-12-08`, retrieved 2026-10-26)
- Started: 2024-11-18 (actual) (ClinicalTrials.gov record NCT04670666, source copy `cardio:ctgov-nct04670666-2025-12-08`, retrieved 2026-10-26)
- Primary completion: 2026-07 (anticipated) (ClinicalTrials.gov record NCT04670666, source copy `cardio:ctgov-nct04670666-2025-12-08`, retrieved 2026-10-26)
- Completion: 2027-06 (anticipated) (ClinicalTrials.gov record NCT04670666, source copy `cardio:ctgov-nct04670666-2025-12-08`, retrieved 2026-10-26)
- Countries: Brazil (ClinicalTrials.gov record NCT04670666, source copy `cardio:ctgov-nct04670666-2025-12-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04670666-2025-12-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): MADALENA ASSOCIATION
- Intervention (Drug): METFORMIN
- Intervention (Drug): EMPAGLIFLOZIN + LINAGLIPTIN
- Intervention (Other): MADALENA ASSOCIATION PLACEBO
- Intervention (Other): METFORMIN PLACEBO
- Intervention (Other): EMPAGLIFLOZIN + LINAGLIPTIN PLACEBO
- Lead sponsor: EMS
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: f968c1ed6c110085b8525634bfc9d82ffb6cf8a214f1c0ddb80cb130a7d5225a
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
